SAR 3419 : An Anti-CD 19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies

@inproceedings{Blanc2011SAR3,
  title={SAR 3419 : An Anti-CD 19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies},
  author={V{\'e}ronique Blanc and A. Bousseau and Anne Caron and Chantal Carrez and Robert J. Lutz and J. G. Lambert},
  year={2011}
}
SAR3419 is a novel anti-CD19 humanized monoclonal antibody conjugated to a maytansine derivate through a cleavable linker for the treatment of B-cell malignancies. SAR3419 combines the strengths of a high-potency tubulin inhibitor and the exquisite B-cell selectivity of an anti-CD19 antibody. The internalization and processing of SAR3419, following its binding at the surface of CD19-positive human lymphoma cell lines and xenograft models, release active metabolites that trigger cell-cycle… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

In vivo testing of drug-linker stability.

Methods in molecular biology • 2013
View 3 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 59 references

Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2009
View 9 Excerpts
Highly Influenced

Preclinical evaluation of SAR3419 (huB4-DM4), an anti-CD19-maytansinoid immunoconjugate, for the treatment of B-cell lymphoma

RJ Lutz, C Zuany-Amorim, +3 authors H Xie
Proc Am Assoc Cancer Res • 2006
View 9 Excerpts
Highly Influenced

Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2011
View 5 Excerpts
Highly Influenced

Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2011
View 7 Excerpts
Highly Influenced

Brentuximab Vedotin (SGN-35).

Clinical cancer research : an official journal of the American Association for Cancer Research • 2011
View 7 Excerpts
Highly Influenced

Investigational antibody-drug conjugates for hematological malignancies.

Expert opinion on investigational drugs • 2011
View 4 Excerpts
Highly Influenced

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)positive breast cancer after prior HER2-directed therapy

Burris HA3rd, RugoHS, +3 authors S Limentani
J Clin Oncol 2011;29:398–405 • 2011
View 4 Excerpts
Highly Influenced

Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2011
View 6 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…